Fig. S12 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijie Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406169.v1

2023-01-01

Abstract:PAFR expression was associated with pSrc, pJAK2, pStat3, or IL-6 expression in 90 primary human NSCLC specimens.

What problem does this paper attempt to address?

Fig. S1 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406178.v1

2023-01-01

Abstract:PAFR positively correlates with the progression of various cancers.
Fig. S11 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406172

2023-01-01

Abstract:PAF/PAFR axis enhanced the strength and duration of Stat3 activation.
Fig. S13 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406166.v1

2023-01-01

Abstract:Effects of PAFR depletion on EMT and Stat3 pathway of NSCLC cells in vivo.
Fig. S14 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406163

2023-01-01

Abstract:Statistical analyses of PAFR, E-cadherin, N-cadherin, vimentin, snail, Zeb-1, pSrc, pJAK2, pStat3, or IL-6 in A549 and H460 tumors stably expressing shPAFR or their respectively control shRNA.
Fig. S4 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijie Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406151

2023-01-01

Abstract:Effects of PAF/PAFR axis on growth and invasion of Calu-3 and H226 cells in vitro.
Fig. S15 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406160

2023-01-01

Abstract:Schematic diagram of the mechanism underlying PAFR-activated Stat3 in the EMT and metastasis of NSCLC.
Fig. S7 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406142

2023-01-01

Abstract:Effects of PAF/PAFR axis on EMT in Calu-3 and H226 cells.
Fig. S5 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijie Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406148.v1

2023-01-01

Abstract:Effects of PAFR inhibitor-WEB2086 on growth and invasion of A549 and H460 cells in vitro.
Fig. S9 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406136

2023-01-01

Abstract:Evaluating the effects of Stat3 shRNA, or it in the presence of 100 nM PAF on the invasion of A549 and H460 cells using transwell invasion assay.
Supplementary Table 2 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijie Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406130.v1

2023-01-01

Abstract:Correlation between the clinicopathologic features and expression of PAFR in NSCLC
Fig. S10 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406175

2023-01-01

Abstract:Evaluating the effects of shRNA vector, PAFR shRNA, Stat3 shRNA, or these shRNAs in the presence of 100 nM PAF on the mRNA level of IL-6 in A549 and H460 cells.
supplementary Table 7 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijie Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406115

2023-01-01

Abstract:Correlation between the clinicopathologic features and expression of PAFR in colon cancer
Supplementary Table 5 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Jie Chen,Tian Lan,Weimin Zhang,Lijia Dong,Nan Kang,Shumin Zhang,Ming Fu,Bing Liu,Kangtai Liu,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22406121

2023-01-01

Abstract:overexpression of PAFR in gastric cancer
Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Kazuhiko Shien,Vassiliki A. Papadimitrakopoulou,Dennis Ruder,Carmen Behrens,Li Shen,Neda Kalhor,Juhee Song,J. Jack Lee,Jing Wang,Ximing Tang,Roy S. Herbst,Shinichi Toyooka,Luc Girard,John D. Minna,Jonathan M. Kurie,Ignacio I. Wistuba,Julie Izzo

DOI: https://doi.org/10.1158/1535-7163.22508793

2023-01-01

Abstract:Figure S2. Downstream pathway molecules activated by IL6 family proinflammatory cytokine stimulation in NSCLC cells. Five NSCLC cell lines were cultured with an IL6 family cytokine (rhIL6, rhOSM, rhLIF; 1 ng/mL) for the indicated time period under serum-starved conditions. Cell lysates were analyzed for the proteins shown by Western blotting.
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Kazuhiko Shien,Vassiliki A Papadimitrakopoulou,Dennis Ruder,Carmen Behrens,Li Shen,Neda Kalhor,Juhee Song,J Jack Lee,Jing Wang,Ximing Tang,Roy S Herbst,Shinichi Toyooka,Luc Girard,John D Minna,Jonathan M Kurie,Ignacio I Wistuba,Julie G Izzo

DOI: https://doi.org/10.1158/1535-7163.MCT-17-0148

2017-01-01

Molecular Cancer Therapeutics

Abstract:Molecularly targeted drugs have yielded significant therapeutic advances in oncogene-driven non-small cell lung cancer (NSCLC), but a majority of patients eventually develop acquired resistance. Recently, the relation between proinflammatory cytokine IL6 and resistance to targeted drugs has been reported. We investigated the functional contribution of IL6 and the other members of IL6 family proinflammatory cytokine pathway to resistance to targeted drugs in NSCLC cells. In addition, we examined the production of these cytokines by cancer cells and cancer-associated fibroblasts (CAF). We also analyzed the prognostic significance of these molecule expressions in clinical NSCLC samples. In NSCLC cells with acquired resistance to targeted drugs, we observed activation of the IL6-cytokine pathway and STAT3 along with epithelial-to-mesenchymal transition (EMT) features. In particular, IL6 family cytokine oncostatin-M (OSM) induced a switch to the EMT phenotype and protected cells from targeted drug-induced apoptosis in OSM receptors (OSMRs)/JAK1/STAT3-dependent manner. The crosstalk between NSCLC cells and CAFs also preferentially activated the OSM/STAT3 pathway via a paracrine mechanism and decreased sensitivity to targeted drugs. The selective JAK1 inhibitor filgotinib effectively suppressed STAT3 activation and OSMR expression, and cotargeting inhibition of the oncogenic pathway and JAK1 reversed resistance to targeted drugs. In the analysis of clinical samples, OSMR gene expression appeared to be associated with worse prognosis in patients with surgically resected lung adenocarcinoma. Our data suggest that the OSMRs/JAK1/STAT3 axis contributes to resistance to targeted drugs in oncogene-driven NSCLC cells, implying that this pathway could be a therapeutic target. (C) 2017 AACR.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
Aberrantly Expressed Fra-1 by Il-6/Stat3 Transactivation Promotes Colorectal Cancer Aggressiveness Through Epithelial-Mesenchymal Transition

Hong Liu,Guoping Ren,Tingyang Wang,Yuexia Chen,Chaoju Gong,Yanfeng Bai,Bo Wang,Hongyan Qi,Jing Shen,Lijun Zhu,Cheng Qian,Maode lai,Jimin Shao

DOI: https://doi.org/10.1093/carcin/bgv017

2015-01-01

Carcinogenesis

Abstract:The pro-inflammatory cytokine interleukin-6 (IL-6) in tumor microenvironment has been suggested to promote development and progression of colorectal cancer (CRC). However, the underlying molecular mechanisms remain elusive. In this study, we demonstrate that fos-related antigen-1 (Fra-1) plays a critical role in IL-6 induced CRC aggressiveness and epithelial-mesenchymal transition (EMT). In CRC cell lines, the expression of Fra-1 gene was found significantly upregulated during IL-6-driven EMT process. The Fra-1 induction occurred at transcriptional level in a manner dependent on signal transducer and activator of transcription 3 (STAT3), during which both phosphorylated and acetylated post-translational modifications were required for STAT3 activation to directly bind to the Fra-1 promoter. Importantly, RNA interference-based attenuation of either STAT3 or Fra-1 prevented IL-6-induced EMT, cell migration and invasion, whereas ectopic expression of Fra-1 markedly reversed the STAT3-knockdown effect and enhanced CRC cell aggressiveness by regulating the expression of EMT-promoting factors (ZEB1, Snail, Slug, MMP-2 and MMP-9). Furthermore, Fra-1 levels were positively correlated with the local invasion depth as well as lymph node and liver metastasis in a total of 229 CRC patients. Intense immunohistochemical staining of Fra-1 was observed at the tumor marginal area adjacent to inflammatory cells and in parallel with IL-6 secretion and STAT3 activation in CRC tissues. Together, this study proposes the existence of an aberrant IL-6/STAT3/Fra-1 signaling axis leading to CRC aggressiveness through EMT induction, which suggests novel therapeutic opportunities for the malignant disease.
JAK/STAT3 Signaling is Required for TGF-β-induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.

Reng-Yun Liu,Yuanyuan Zeng,Zhe Lei,Longqiang Wang,Haiping Yang,Zeyi Liu,Jun Zhao,Hong-Tao Zhang

DOI: https://doi.org/10.3892/ijo.2014.2310

2014-01-01

International Journal of Oncology

Abstract:Epithelial-mesenchymal transition (EMT), a key step in the early stages of cancer metastasis, is orchestrated by several signaling pathways, including IL-6/JAK/STAT3 and TGF-β/Smad signaling. However, an association between the two signaling pathways during the EMT process is largely unknown. Here, we focused on lung cancer and demonstrated that TGF-β1 induced the phosphorylation of Smad3 (p-Smad3), upregulation of Snail, a fibroblast-like morphology, and downregulation of E-cadherin as well as upregulation of vimentin in lung cancer cell lines. SIS3 (an inhibitor of Smad3) suppressed TGF-β1-induced activation of Smad3, upregulation of Snail and the EMT process. Importantly, the JAK2/STAT3-specific inhibitor AG490 blocked Stat3 phosphorylation, resulting in attenuated levels of TGF-β1-induced p-Smad3, Snail, MMP2, and Smad-mediated PAI-1 promoter reporter gene activity in A549 and H1650 cells. Subsequently, AG490 inhibited TGF-β-induced cell migration and invasion. Moreover, exogenous IL-6 treatment stimulated Stat3 activation, enhanced TGF-β-induced expression of p-Smad3 and Snail, aggravated the EMT process, and increased lung cancer cell migration and invasion induced by TGF-β1. Our findings show that the JAK/STAT3 pathway is required for TGF-β-induced EMT and cancer cell migration and invasion via upregulation of the expression of p-Smad3 and Snail, and the IL-6/JAK/STAT3 and TGF-β/Smad signaling synergistically enhance EMT in lung carcinomas. The present study suggests a novel rationale for inhibiting cancer metastasis using anti-IL-6/JAK/STAT3 and anti-TGF-β/Smad therapeutic strategies.

Fig. S12 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S1 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S11 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S13 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S14 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S4 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S15 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S7 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S5 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S9 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Supplementary Table 2 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Fig. S10 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

supplementary Table 7 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Supplementary Table 5 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Aberrantly Expressed Fra-1 by Il-6/Stat3 Transactivation Promotes Colorectal Cancer Aggressiveness Through Epithelial-Mesenchymal Transition

JAK/STAT3 Signaling is Required for TGF-β-induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.